Compare New Era Energy & Digital Inc. Common Stock (NUAI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New Era Energy & Digital Inc. Common Stock vs Tango Therapeutics Inc. — how do they compare? New Era Energy & Digital Inc. Common Stock trades at $3.44 (market cap $518.22M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 7.2× New Era Energy & Digital Inc. Common Stock's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, New Era Energy & Digital Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold New Era Energy & Digital Inc. Common Stock for 2 Days and Tango Therapeutics Inc. for 0 Days on average.
| NUAI | TNGX | |
|---|---|---|
Market Cap | $518.22M | $3.75B |
Volume | 7,267,523 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $8.06 | $32.90 |
52-Week Low | $2.37 | $7.50 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $463.57M | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUAI trades at $4.29, down 1.15% today, with a bearish technical signal despite recent positive news about a 20-year power deal for its Texas data center project. The company shows severe financial stress with negative margins (-5,985.71% net income margin) and consecutive quarterly losses, though analyst consensus remains bullish with a $10.67 price target. Recent institutional interest includes BlackRock's new stake in Q2 2026.
The stock presents high-risk speculation with potential upside if data center development succeeds, but faces substantial execution and funding risks. Current fundamentals are weak, making it suitable only for risk-tolerant investors betting on future project milestones and hyperscaler partnerships.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About New Era Energy & Digital Inc. Common Stock
New Era Energy & Digital develops large-scale data centers in energy-rich U.S. markets for AI training and inference workloads. Its Texas Critical Data Centers project in the Permian Basin combines modular deployment with flexible power solutions.
Read more on NUAI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
